GH Research GHRS
NASDAQ GHRS
$28.23 +0.31 (+1.11%)
As of: Sep 4, 2026 · 3:59 PM EDT

GH Research (GHRS) Operating Leases (2023 - 2026)

GH Research (GHRS) posted quarterly Operating Leases of $365000.0 for Q4 2025, down 1.08% year-over-year from $369000.0 in Q4 2024, and little changed quarter-over-quarter from $365000.0 in Q3 2025.

Analysis

GH Research (GHRS) Operating Leases (2023 - 2026) Analysis & Trends

GH Research's Operating Leases history runs 3 years deep, the most recent figure standing at $365000.0 for Q4 2025.

  • In Q4 2025, Operating Leases fell 1.08% year-over-year to $365000.0; the TTM figure through Dec 2025 stood at $365000.0 (down 1.08% YoY), while the FY2025 annual figure was $365000.0, down 1.08% from the prior year.
  • Operating Leases for Q4 2025 stood at $365000.0, roughly flat from $365000.0 in the prior quarter.
  • The five-year high for Operating Leases was $1.0 million in Q4 2023, with the low at $336000.0 in Q1 2025.
  • The 3-year median for Operating Leases is $477500.0 (2024), against an average of $541583.3.
  • The sharpest annual moves came in 2024 and 2025: Operating Leases sank 63.1% in 2024, then decreased 1.08% in 2025.
  • GH Research's Operating Leases stood at $1.0 million in 2023, then tumbled by 63.1% to $369000.0 in 2024, then slipped by 1.08% to $365000.0 in 2025.
  • Business Quant data shows GHRS's Operating Leases at $365000.0 in Q4 2025, $365000.0 in Q3 2025, and $364000.0 in Q2 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 GH Research 1.72 Bn 1.36 Bn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 354,000.00
Mar 31, 2026 357,000.00
Dec 31, 2025 365,000.00
Sep 30, 2025 365,000.00
Jun 30, 2025 364,000.00
Mar 31, 2025 336,000.00
Dec 31, 2024 369,000.00
Sep 30, 2024 275,000.00
Jun 30, 2024 263,000.00
Mar 31, 2024 336,000.00
Dec 31, 2023 1.00 Mn
Sep 30, 2023 260,000.00
Jun 30, 2023 267,000.00
Mar 31, 2023 334,000.00